Effect of substituting IPV for tOPV on immunity to poliovirus in Bangladeshi infants: An open-label randomized controlled trial

Highlights • We tested two poliovirus vaccination regimens substituting IPV for the 4th EPI tOPV dose. • Neither regimen gave superior intestinal mucosal immunity measured by 1-year poliovirus shedding. • The two regimens were equivalent within a 95%CI margin of prevalence of shedding of −10% to +4%...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2016-01, Vol.34 (3), p.358-366
Main Authors: Mychaleckyj, Josyf C, Haque, Rashidul, Carmolli, Marya, Zhang, Dadong, Colgate, E. Ross, Nayak, Uma, Taniuchi, Mami, Dickson, Dorothy, Weldon, William C, Oberste, M. Steven, Zaman, K, Houpt, Eric R, Alam, Masud, Kirkpatrick, Beth D, Petri, William A
Format: Article
Language:English
Subjects:
Age
Allergy and Immunology
Bangladesh
ClinicalTrials.gov NCT01375647
Disease control
Feces
Feces - virology
Humans
Immunity, Mucosal
Immunization
Inactivated poliovirus vaccine
Infant
Infants
Intestinal immunity
Laboratories
Mothers
Oral poliovirus vaccine
Poliomyelitis
Poliomyelitis - prevention & control
Poliovirus
Poliovirus Vaccine, Inactivated - administration & dosage
Poliovirus Vaccine, Inactivated - immunology
Public health
Serum neutralizing antibody
Shedding
Vaccines
Virus Shedding
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • We tested two poliovirus vaccination regimens substituting IPV for the 4th EPI tOPV dose. • Neither regimen gave superior intestinal mucosal immunity measured by 1-year poliovirus shedding. • The two regimens were equivalent within a 95%CI margin of prevalence of shedding of −10% to +4%. • Results for shedding analyses stratified by poliovirus type were similar. • IPV regimen strongly enhanced humoral immunity with higher sero-prevalence and -conversion.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.11.046